Scandinavian Real Heart AB (Publ)

Stockholm Stock Exchange HEART.ST

Scandinavian Real Heart AB (Publ) EBITDA Margin for the year ending December 31, 2023

Scandinavian Real Heart AB (Publ) EBITDA Margin is NA for the year ending December 31, 2023. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Scandinavian Real Heart AB (Publ) EBITDA Margin for the year ending December 31, 2022 was -137,348.44%.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
Stockholm Stock Exchange: HEART.ST

Scandinavian Real Heart AB (Publ)

CEO Dr. Ina Laura Perkins
IPO Date Nov. 26, 2014
Location Sweden
Headquarters Kopparbergsvägen 6
Employees 15
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Scandinavian Real Heart AB (Publ) designs and develops an artificial heart. It engages in developing Realheart TAH to treat advanced stage heart failure. It also develops RealVAD, PulsePump, and Sternal Prosthesis products. The company was incorporated in 2007 and is based in Västerås, Sweden.

StockViz Staff

January 15, 2025

Any question? Send us an email